A need of the hour: pharmacovigilance in healthcare setting – nothing less than safety
Keywords:
Key words: Adverse drug reactions (ADR), PVPI, AMC, CMEAbstract
Introduction: Pharmacovigilance (PV) is crucial to identify, managing, and reporting adverse drug reactions (ADRs) in the healthcare sector. Young healthcare professionals (HCPs) play an essential role in the PV system. Objective: This study aimed to assess awareness, understand the causes of underreporting, and find solutions to encourage ADR reporting among young HCPs. Methods: This prevalidated, questionnaire-based, cross-sectional study aimed to evaluate the knowledge, attitude, perception, and strategies to improve PV reporting among 152 young HCP interns at a teaching hospital in India. The study was conducted in January 2023 and approved by the ethics committee. The responses were analysed using a Microsoft Excel worksheet. Results In a study of 152 interns, 97.3% agreed that pharmacovigilance (PV) may assist patients, but only 56% had experienced adverse drug reactions (ADRs) in practise. Only 40.5% chose email reporting, and 65.8% did not have a nearby ADR Monitoring Centre (AMC). More over half (53%) thought ADRs should only be reported to an AMC. Training sessions were underutilised, with only 28.6% attending PVPI training. The difficulty in identifying the causal substance, as well as a lack of incentives, were important reasons for underreporting. Continuing medical education/workshops were mentioned by 96% of young HCPs as a way to encourage reporting. Conclusion: According to the study, while young HCPs are aware of PV, there is a need for more training and incentives to enhance ADR reporting. Encouragement of National Pharmacovigilance Week and the availability of neighbouring AMCs could further aid raise PV awareness.
Keywords: Adverse drug reactions (ADR), PVPI, AMC, CME
Downloads
References
Published
Issue
Section
License
Copyright (c) 2023 Preeti Shanbhag, Satish S , Mr.Ramdas Bhat, A R Shabaraya
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.
